Oculis Holding AG (OCS) Stock Analysis & Investment Frameworks
Oculis Holding AG (OCS) stock analysis on Invetso. Review Oculis Holding AG’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Oculis Holding AG Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
Oculis Holding AG Key Financial Metrics
- Market Cap: $484.70M
- Revenue: $N/A
- ROE: -42.92%
- ROIC: -38.94%
- Dividend Yield: N/A
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Oculis Holding AG Investment Frameworks
Invetso analyzes Oculis Holding AG (OCS) across the following frameworks:
- Oculis Holding AG 10Y Growth Potential
- Oculis Holding AG Scenario Analysis
- Oculis Holding AG Risks & Opportunities
- Oculis Holding AG Economic Moat
- Oculis Holding AG Business Model
- Oculis Holding AG Management
- Oculis Holding AG SWOT Analysis
- Oculis Holding AG Porter's 5 Forces
- Oculis Holding AG PESTLE Analysis
- Oculis Holding AG ESG Analysis